Intas Pharmaceuticals Ltd and Henlius Biotech enter into Exclusive License Agreement to commercialise serplulimab - A Novel Anti-PD1 mAb in Europe & India

Oct 28, 2023

Ahmedabad (Gujarat) [India], October 28: Intas Pharmaceuticals Limited ("Intas") has entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the...

Kashiv BioSciences and Intas Pharmaceuticals Sign an Exclusive Licensing and Supply Agreement for Complex Peptide Product in Europe, the UK & India

Feb 11, 2026

Piscataway (New Jersey) [US], February 11: Kashiv BioSciences, LLC ("Kashiv") a vertically integrated biopharmaceutical company, today announced that it has entered into an exclusive...

Intas and Henlius receive positive CHMP opinion for HETRONIFLY® (HANSIZHUANG in China) as first-line treatment for extensive-stage small cell lung cancer

Sep 25, 2024

Ahmedabad (Gujarat) [India], September 25: Intas Pharmaceuticals Limited ("Intas") has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...

Intas launches the World's first SB-100mg Itraconazole

Oct 16, 2021

Ahmedabad (Gujarat) [India], October 16(ANI/PNN): One of the world's leading pharmaceutical companies, Intas Pharmaceuticals, has made a progressive breakthrough in the Antifungal Therapy domain...

European Medicine Agency accepts Intas' Marketing Authorization Application for DMB-3115, a Proposed Biosimilar to Stelara (Ustekinumab)

Jul 14, 2023

Ahmedabad (Gujarat) [India], July 14: Intas Pharmaceuticals Ltd. announced that the European Medicine Agency (EMA) confirms acceptance of the Marketing Authorization Application (MAA) for...

Intas Pharmaceuticals Ltd. marches into the Guinness World Records

Nov 21, 2022

Ahmedabad (Gujarat) [India], November 21 (ANI/PRNewswire): Intas Pharmaceuticals Ltd., one of the leading pharmaceutical multinationals, has successfully set a Guinness World Record by creating...